» Articles » PMID: 18061305

Detection and Comparison of Epidermal Growth Factor Receptor Mutations in Cells and Fluid of Malignant Pleural Effusion in Non-small Cell Lung Cancer

Overview
Journal Lung Cancer
Specialty Oncology
Date 2007 Dec 7
PMID 18061305
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Cells or cell-free fluid of malignant pleural effusion could be important clinical specimen for epidermal growth factor receptor (EGFR) mutation screening in advanced non-small cell lung cancer (NSCLC) patients. However, their usefulness in mutation detection has not been well compared. In this study we recruited 26 East Asian NSCLC patients with malignant pleural effusion, determined the mutation status of EGFR in both cells and matched cell-free fluid with the use of sequencing and mutant-enriched PCR. After comparing the mutation spectrums, we found both the cells and cell-free pleural fluid may be feasible clinical specimen for EGFR mutation detection in unresectable NSCLC given sensitive genotyping assays employed. Direct sequencing could miss a significant portion of mutations in these heterogeneous specimens. More sensitive methods, such as mutant-enriched PCR and gene scan, could provide more reliable mutational information.

Citing Articles

Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study.

Chang S, Wei Y, Chen C, Lai Y, Hu P, Hung J Mol Diagn Ther. 2024; 28(6):803-810.

PMID: 39147938 PMC: 11512990. DOI: 10.1007/s40291-024-00736-8.


Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.

Sorolla M, Sorolla A, Parisi E, Salud A, Porcel J Cancers (Basel). 2021; 13(11).

PMID: 34199799 PMC: 8200094. DOI: 10.3390/cancers13112798.


Utilizing Publicly Available Cancer Clinicogenomic Data on CBioPortal to Compare Epidermal Growth Factor Receptor Mutant and Wildtype Non-Small Cell Lung Cancer.

Dhar C Cureus. 2021; 13(4):e14683.

PMID: 34055528 PMC: 8149776. DOI: 10.7759/cureus.14683.


Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion.

Miao Z, Mu T, Liu L, Rao J, Jin M, Wang Z Front Oncol. 2020; 10:561341.

PMID: 33194628 PMC: 7645070. DOI: 10.3389/fonc.2020.561341.


A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.

Jin S, Zhou C, Hou X, Fan Z, Zhao J, Ai X Transl Lung Cancer Res. 2020; 9(4):1507-1515.

PMID: 32953522 PMC: 7481626. DOI: 10.21037/tlcr-20-882.